authors
- Renouf, DJ
- Knox, JJ
- Kavan, P
- Jonker, D
- Welch, S
- Couture, F
- Lemay, F
- Tehfe, M
- Harb, M
- Aucoin, N
- Ko, Y-J
- Tang, P
- Ramjeesingh, R
- Meyers, Brandon
- Kim, C
- Schaeffer, DF
- Loree, J
- Gill, S
- Tu, D
- O'Callaghan, C
LBA65 The Canadian Cancer Trials Group PA.7 trial: Results of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)
Conferences
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
status
publication date
- September 2020
has subject area
- 1112 Oncology and Carcinogenesis (FoR)
- Oncology & Carcinogenesis (Science Metrix)
published in
- Annals of Oncology Journal
presented at event
- ESMO Virtual Congress Conference